Literature DB >> 12146847

Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US.

Laurel A Habel1, Wei Zhao, Janet L Stanford.   

Abstract

OBJECTIVE: To examine the relationship between daily aspirin use and risk of prostate cancer in a large, racially diverse cohort of men followed for up to 32 years.
METHODS: The study population included 90,100 male subscribers to the Kaiser Permanente Medical Care Program who had received one or more multiphasic health checkups between 1964 and 1973. This general health checkup included a self-completed questionnaire that requested men to record if they took more than six aspirin almost every day during the previous year. Subjects were followed for the development of prostate cancer using the local tumor registry. Cox regression was used to estimate relative risks (RR) and 95% confidence intervals (CI).
RESULTS: A total of 2,574 men developed prostate cancer. Of these, 1617 had local stage disease and 719 had either regional or distant disease at diagnosis. A total of 2466 men (2.7%) reported taking more than six aspirin almost every day during the past year at one or more health checkups. After adjusting for birth year, education, race, and the number of health checkups. the relative risk of prostate cancer associated with this amount of aspirin use was 0.76 (95% CI 0.60-0.98). Relative risks did not differ by race and were similar for both local stage and regional or distant stage prostate cancer.
CONCLUSION: Results from our large, multiracial cohort study support a modest inverse relationship between daily consumption of more than six aspirin and prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12146847     DOI: 10.1023/a:1015788502099

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  35 in total

Review 1.  A review of African American-white differences in risk factors for cancer: prostate cancer.

Authors:  Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

2.  Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies.

Authors:  Tian-Bao Huang; Yang Yan; Zhui-Feng Guo; Xiao-Long Zhang; Huan Liu; Jiang Geng; Xu-Dong Yao; Jun-Hua Zheng
Journal:  Int Urol Nephrol       Date:  2014-04-01       Impact factor: 2.370

Review 3.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

Review 4.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

5.  Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk.

Authors:  Claudia A Salinas; Erika M Kwon; Liesel M FitzGerald; Ziding Feng; Peter S Nelson; Elaine A Ostrander; Ulrike Peters; Janet L Stanford
Journal:  Am J Epidemiol       Date:  2010-08-05       Impact factor: 4.897

6.  A novel computational approach for drug repurposing using systems biology.

Authors:  Azam Peyvandipour; Nafiseh Saberian; Adib Shafi; Michele Donato; Sorin Draghici
Journal:  Bioinformatics       Date:  2018-08-15       Impact factor: 6.937

7.  Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006.

Authors:  Preet K Dhillon; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2011-02-26       Impact factor: 7.396

8.  Intratumoral inflammation is associated with more aggressive prostate cancer.

Authors:  Joseph C Klink; Lionel L Bañez; Leah Gerber; Amy Lark; Robin T Vollmer; Stephen J Freedland
Journal:  World J Urol       Date:  2013-04-02       Impact factor: 4.226

Review 9.  Chemoprevention of prostate cancer: what can be recommended to patients?

Authors:  Janet L Colli; Christopher L Amling
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

10.  Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.

Authors:  Kevin S Choe; Janet E Cowan; June M Chan; Peter R Carroll; Anthony V D'Amico; Stanley L Liauw
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.